The latest news from debra of America, from organizational happenings and inspiring stories to expert insights and research updates.
News & Blog
Bridging Gaps and Moving Forward: Our Wound Care Distribution Program Journey
In the heart of debra of America’s mission to support those battling Epidermolysis Bullosa (EB), is our Wound Care Distribution Program. With the recent relocation of our headquarters from New York to Colorado, we're not just changing our address; we're enhancing our capacity to serve and support…
We've Moved our HQ to Boulder, CO!
Exciting news —After four decades in the bustling Big Apple, we’ve moved our headquarters to beautiful Boulder, Colorado! This new location will allow our dedicated team to better serve and support our Epidermolysis Bullosa (EB) Community.
Our office is located at 1023 Walnut Street, Suite 100,…
The U.S. FDA Approves FILSUVEZ topical gel for JEB and DEB
debra of America is thrilled to announce a groundbreaking milestone for the Epidermolysis Bullosa (EB) Community: The U.S. Food and Drug Administration (FDA) has granted approval for FILSUVEZ® (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and…
#GivingTuesday Spotlight: Scott Kerns
Today marks #GivingTuesday, a global generosity movement unleashing the power of people and organizations to transform their communities and the world. As we reflect on the incredible individuals who have made a lasting impact on debra of America’s mission, we are thrilled to shine a spotlight on…
#GivingTuesday Spotlight: Willistine Lenon
As we approach #GivingTuesday, a day dedicated to the spirit of generosity and giving back, we are delighted to shine a spotlight on a special supporter and advocate —Willistine Lenon, Vice President of Clinical Operations at Aegle Therapeutics, a biotechnology company that is developing an…
The U.S. FDA Accepts Pz-cel for Priority Review and Sets PDUFA Date
Big news from Abeona Therapeutics —The U.S. Food and Drug Administration has granted Priority Review for the Biologics License Application for Pz-cel (prademagene zamikeracel), which means that they are fast-tracking their decision on whether to approve it. The FDA is aiming to make that decision…
A Night Filled with Hope: The 2023 debra of America Annual Benefit
On Saturday, November 4, 2023, we celebrated the incredible strides being made in Epidermolysis Bullosa (EB) research and the progress that is yet to come at the debra of America Annual Benefit at the stunning Georgia Aquarium in Atlanta, GA. We honored several EB trailblazers and championed our…
BioMendics to be honored with Partners in Progress Award
BioMendics is set to be honored with the Partners in Progress Award at the debra of America Annual Benefit on Saturday, November 4, 2023 at Georgia Aquarium in Atlanta, GA. There’s still time to get your tickets!
BioMendics was founded by a passionate group of professionals and investors looking…
Eliksa Therapeutics to be honored with Partners in Progress Award
On Saturday, November 4, 2023, Eliksa Therapeutics will be honored with the Partners in Progress Award at the debra of America Annual Benefit at Georgia Aquarium in Atlanta, GA. RSVP here!
Eliksa Therapeutics is a biotech company developing a novel eye drop (ELK-003) to treat corneal abrasions…
Reclaiming Beauty: Ariana Covarrubias and the ONE/SIZE Campaign
In a world obsessed with unattainable beauty standards, there are individuals like Ariana Covarrubias who not only challenge these norms but shatter them entirely. Ariana, a young woman living with Recessive Dystrophic Epidermolysis Bullosa (RDEB), was recently featured in a beauty campaign for ONE…
